by Hospital Acquired Infection Treatment Market Rides on Increased Prevalence of HAI Worldwide
A hospital-acquired infection (HAI) is also otherwise known as a nosocomial infection. It is a type of infection that is contacted in a healthcare facility or in a hospital. The infection is also known as health care–associated infection in an effort to emphasize on both non-hospital and hospital settings. A rise in the incidences of such an infection is expected to give a boost to the global hospital acquired infection treatment market over the timeframe of projection.
Fungal, bacterial, and viral pathogens cause hospital-acquired infections. The most common types are surgical site infection (SSI), urinary tract infection (UTI), pneumonia (such as ventilator-associated pneumonia), and bloodstream infection (BSI).
Get the sample copy of report@ https://qyresearchmedical.com/sample/111895
Market Growth to be driven by Vulnerability of Newborn Babies toward HAI
In some cases, hospital acquired infection manifests itself weeks after discharge from the hospital though it had been contacted in the hospital. The infection could also infect the hospital staff and caregivers associated with taking care of such patients. Such high prevalence and contagiousness of the infection is likely to spell growth for the global hospital acquired infection treatment market in near future.
Many antimicrobial drugs have proven to be highly effective in treating a wide range of hospital-related infections that are highly prevalent across the globe. Treatments of hospital-acquired infections comprise the following
- Antifungal therapy
- Antiviral therapy
The most sterilized sections of the hospital are the neonatal intensive care units (NICUs), which keeps infants as they are more vulnerable to such infections during the span of their hospital stay. The National Institute of Child Health and Human Development (NICHD) conducted a study titled “Neonatal Network”. The study projected that around 29% of the infants born at 25 to 28 weeks of gestation period and 46% of the newborns born at less than 25 weeks of gestation are estimated to experience severe hospital acquired infection over the period of hospitalization at NICU. High vulnerability of infants likely to play an important role in the development of the global hospital acquired infection treatment market in near future.
The global hospital acquired infection treatment (HAI) market for the historical period 2017–2018 and forecast period 2019–2027, unhygienic conditions and improper sterilization treatment, lack of surveillance systems for HAIs, high susceptibility of neonatal population, and rising geriatric population are projected to drive the global hospital acquired infection treatment (HAI) market during the forecast period
According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027
fa global hospital acquired infection treatment market
To know the scope of our report Get a Sample on Hospital Acquired Infection Treatment Market
Rising Geriatric Population and Unhygienic Conditions and Improper Sterilization Treatment: Key Drivers
Continuous increase in the geriatric population is expected to be one of the potential drivers of the hospital acquired infection (HAI) treatment market during the forecast period. The geriatric population is at high risk of infection due to the age-related immunity decline, known as immunosenescence. Moreover, such patients required more time to heal and hospital stay to get recovered.
Increase in need for effective antibacterial treatment options for the geriatric population is expected to drive the demand for the hospital acquired infection treatment (HAI) market
According to WHO estimates, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, which is currently 566 million.
Hospital acquired infections are one the highly frequent adverse events in the health care industry. Presence of unhygienic conditions around and inside the hospital along with improper sterilization techniques applied in the hospitals are increasing the prevalence of hospital acquired infection in low income and middle income countries.
According to an article published by Global Antibiotic Resistance Partnership (GARP), more than 190,000 neonatal deaths occurred in India annually due to infection
Get a glimpse of the in-depth analysis through our Report Brochure
Lack of Surveillance Systems for HAIs Boost Market Growth
Increasing prevalence of HAIs is because most countries do not have surveillance systems for HAIs, while the countries that have the systems in place often face difficulties with the complexity and lack of standardized criteria for diagnosing the infections. Countries in North America and Europe have surveillance systems for HAI monitoring while countries in Asia Pacific and rest of the world do not have the systems, which makes it difficult to control the outbreak of endemics in these regions.
The Healthcare-Associated Infections Surveillance Network (HAI-Net), National Healthcare Safety Network (NHSN), and Japan Nosocomial Infection Surveillance System (JANIS) are some of the surveillance systems working efficiently in developed countries
Multi-drug Resistant Bacteria Making Presently Available Antibacterial Drugs Outdated to Hamper Market
Multi-drug resistance is one of the most common causes of failure in treatment for bacterial infection. Bacteria are the only species that can survive even after frequent exposure to one or more antibiotics and develop drug resistance.
Moreover, these infections result in higher rate of disability and death compared to the infections that are easily treatable with antibiotics. Multi-drug resistance is affecting the HAI treatment market due to the shift of treatment process.
Major types of multi-drug resistant bacteria are methicillin resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB).
Global Hospital Acquired Infection Treatment (HAI) Market: Competitive Landscape
This report profiles major players in the global hospital acquired infection treatment (HAI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global hospital acquired infection treatment (HAI) market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global hospital acquired infection treatment (HAI) market
- Abbott Laboratories
- Pfizer, Inc.
- Bayer AG
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Cipla Inc.
- GlaxoSmithKline plc
- Aridis Pharmaceuticals, Inc
- Astellas Pharma Inc.
- Daiichi Sankyo, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company among others.
Key Questions Answered in Global Hospital acquired infection treatment (HAI) Market Report
- What is the scope of growth of product companies in the global hospital acquired infection treatment (HAI) market?
- What will be the Y-o-Y growth of the global hospital acquired infection treatment (HAI) market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global hospital acquired infection treatment (HAI) market?
- Will North America continue to be the most profitable market for hospital acquired infection treatment (HAI) providers?
- Which factors are anticipated to hamper the growth of the global hospital acquired infection treatment (HAI) market during the forecast period?
- Which are the leading companies in the global hospital acquired infection treatment (HAI) market?
Global Hospital acquired infection treatment (HAI) Market – Segmentation
Infection Type
- Urinary Tract Infection
- Ventilator-Associated Pneumonia
- Bloodstream Infection
- Surgical Site Infection
- Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
Treatment
- Antibacterial Treatment
- Beta-Lactams
- Quinolones
- Vancomycin
- Other
- Antiviral Treatment
- Acyclovir
- Foscarnet
- Antifungal Treatment
- Amphotericin B
- Triazoles
- Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- E-Commerce
- Other
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111895/2900
